Ionis Pharmaceuticals Gets $40M Milestone Payment From Biogen

Carlsbad-based Ionis Pharmaceuticals, a developer of treatments for infantile-onset spinal muscular atrophy (SMA), said it has received $40M more in a milestone payment from Biogen. Ionis said the payment was related to pricing approval for SPINRAZA in Japan. Ions says it has now earned more than $435M from Biogen related to SPINRAZA. Ionis Pharmacueticals said the compound is now available in the U.S., EU, Japan, Canada and Brazil.